FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285087486> ?p ?o ?g. }

• W4285087486 endingPage "70" @default.
• W4285087486 startingPage "61" @default.
• W4285087486 abstract "Abstract Background Andrographolide (Andro) has been confirmed to ameliorate alveolar hypercoagulation and fibrinolysis inhibition via NF-κB pathway in acute respiratory distress syndrome (ARDS), but the specific target of Andro is unknown. Purpose Our aim is to explore the specific target of Andro through which the drug exerted its effects on alveolar hypercoagulation and fibrinolytic inhibition in LPS-induced ARDS. Methods AECII was treated with different doses of Andro for 1 h, and then stimulated with LPS for 24 h. Expressions of tissue factor (TF), plasminogen activator inhibitor (PAI)-1 and tissue factor pathway inhibitor (TFPI) were detected. Concentrations of thrombin-antithrombin complex (TAT), pro-collagen type III peptide (PIIIP), antithrombin III (ATIII) and activated protein C (APC) in cell supernatant were measured by enzyme linked immunosorbent assay (ELISA). NF-κB signaling pathways activation was simultaneously determined. AECII with p65 down-/over-expression were used as control. Results Andro effectively inhibited TF and PAI-1 and promoted TFPI expressions on AECII induced by LPS stimulation. Andro also significantly suppressed the productions of TAT and PIIIP but promoted ATIII and APC secretions from the LPS-treated cell. Furthermore, Andro application obviously inhibited NF-κB signaling pathway activation provoked by LPS, as shown by decreased level of phosphorylation (p‑)-IKKβ/IKKβ, p-p65/p65 and p65 DNA binding activity. The effects of Andro on those factors were obviously strengthened by down- but were weakened by up-regulation of p65 gene in AECII cell. Conclusions Our data demonstrates that targeting AECII is the mechanism by which Andro ameliorates alveolar hypercoagulaiton and fibrinolytic inhibition via NF-κB pathway in ARDS. Andro is worth to be clinically further studied in ARDS treatment." @default.
• W4285087486 created "2022-07-14" @default.
• W4285087486 creator A5006293284 @default.
• W4285087486 creator A5009232538 @default.
• W4285087486 creator A5022021193 @default.
• W4285087486 creator A5030381486 @default.
• W4285087486 creator A5053780153 @default.
• W4285087486 creator A5084792906 @default.
• W4285087486 creator A5089824328 @default.
• W4285087486 date "2022-07-13" @default.
• W4285087486 modified "2023-10-17" @default.
• W4285087486 title "Andrographolide Suppresses Expressions of Coagulation and Fibrinolytic Inhibition-Related Factors in LPS-Induced Alveolar Epithelial Cell Type II via NF-κB Signal Pathway In Vitro" @default.
• W4285087486 cites W1604909258 @default.
• W4285087486 cites W2038332551 @default.
• W4285087486 cites W2093852073 @default.
• W4285087486 cites W2110002099 @default.
• W4285087486 cites W2150432126 @default.
• W4285087486 cites W2156771080 @default.
• W4285087486 cites W2548097234 @default.
• W4285087486 cites W2624647150 @default.
• W4285087486 cites W2891631522 @default.
• W4285087486 cites W2900684198 @default.
• W4285087486 cites W2913810523 @default.
• W4285087486 cites W2969447749 @default.
• W4285087486 cites W3031259648 @default.
• W4285087486 cites W3105668712 @default.
• W4285087486 cites W3109979035 @default.
• W4285087486 cites W3117955968 @default.
• W4285087486 cites W3130785861 @default.
• W4285087486 cites W3200569029 @default.
• W4285087486 cites W3202438914 @default.
• W4285087486 cites W3202905100 @default.
• W4285087486 cites W4294658238 @default.
• W4285087486 doi "https://doi.org/10.1007/s44231-022-00010-7" @default.
• W4285087486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36523372" @default.
• W4285087486 hasPublicationYear "2022" @default.
• W4285087486 type Work @default.
• W4285087486 citedByCount "2" @default.
• W4285087486 countsByYear W42850874862023 @default.
• W4285087486 crossrefType "journal-article" @default.
• W4285087486 hasAuthorship W4285087486A5006293284 @default.
• W4285087486 hasAuthorship W4285087486A5009232538 @default.
• W4285087486 hasAuthorship W4285087486A5022021193 @default.
• W4285087486 hasAuthorship W4285087486A5030381486 @default.
• W4285087486 hasAuthorship W4285087486A5053780153 @default.
• W4285087486 hasAuthorship W4285087486A5084792906 @default.
• W4285087486 hasAuthorship W4285087486A5089824328 @default.
• W4285087486 hasBestOaLocation W42850874861 @default.
• W4285087486 hasConcept C126322002 @default.
• W4285087486 hasConcept C134018914 @default.
• W4285087486 hasConcept C153911025 @default.
• W4285087486 hasConcept C170493617 @default.
• W4285087486 hasConcept C185592680 @default.
• W4285087486 hasConcept C186738567 @default.
• W4285087486 hasConcept C2776348555 @default.
• W4285087486 hasConcept C2776825266 @default.
• W4285087486 hasConcept C2777151630 @default.
• W4285087486 hasConcept C2777557582 @default.
• W4285087486 hasConcept C2777714996 @default.
• W4285087486 hasConcept C2777730290 @default.
• W4285087486 hasConcept C2778382381 @default.
• W4285087486 hasConcept C2779026020 @default.
• W4285087486 hasConcept C2779679481 @default.
• W4285087486 hasConcept C2779730028 @default.
• W4285087486 hasConcept C2780675426 @default.
• W4285087486 hasConcept C2781287897 @default.
• W4285087486 hasConcept C55493867 @default.
• W4285087486 hasConcept C62478195 @default.
• W4285087486 hasConcept C71924100 @default.
• W4285087486 hasConcept C86803240 @default.
• W4285087486 hasConcept C88045685 @default.
• W4285087486 hasConcept C95444343 @default.
• W4285087486 hasConcept C98274493 @default.
• W4285087486 hasConceptScore W4285087486C126322002 @default.
• W4285087486 hasConceptScore W4285087486C134018914 @default.
• W4285087486 hasConceptScore W4285087486C153911025 @default.
• W4285087486 hasConceptScore W4285087486C170493617 @default.
• W4285087486 hasConceptScore W4285087486C185592680 @default.
• W4285087486 hasConceptScore W4285087486C186738567 @default.
• W4285087486 hasConceptScore W4285087486C2776348555 @default.
• W4285087486 hasConceptScore W4285087486C2776825266 @default.
• W4285087486 hasConceptScore W4285087486C2777151630 @default.
• W4285087486 hasConceptScore W4285087486C2777557582 @default.
• W4285087486 hasConceptScore W4285087486C2777714996 @default.
• W4285087486 hasConceptScore W4285087486C2777730290 @default.
• W4285087486 hasConceptScore W4285087486C2778382381 @default.
• W4285087486 hasConceptScore W4285087486C2779026020 @default.
• W4285087486 hasConceptScore W4285087486C2779679481 @default.
• W4285087486 hasConceptScore W4285087486C2779730028 @default.
• W4285087486 hasConceptScore W4285087486C2780675426 @default.
• W4285087486 hasConceptScore W4285087486C2781287897 @default.
• W4285087486 hasConceptScore W4285087486C55493867 @default.
• W4285087486 hasConceptScore W4285087486C62478195 @default.
• W4285087486 hasConceptScore W4285087486C71924100 @default.
• W4285087486 hasConceptScore W4285087486C86803240 @default.
• W4285087486 hasConceptScore W4285087486C88045685 @default.
• W4285087486 hasConceptScore W4285087486C95444343 @default.
• W4285087486 hasConceptScore W4285087486C98274493 @default.

• next